Dipyridamole acts by –
**Core Concept**
Dipyridamole is an antiplatelet medication that inhibits platelet activation and aggregation. It does so by increasing the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) within platelets, leading to vasodilation and inhibition of platelet function.
**Why the Correct Answer is Right**
Dipyridamole achieves this by inhibiting the enzyme phosphodiesterase, which breaks down cAMP and cGMP. As a result, the levels of these cyclic nucleotides increase, leading to the activation of protein kinase A (PKA) and protein kinase G (PKG). PKA and PKG then phosphorylate and inhibit key enzymes involved in platelet activation, such as phospholipase C and calcium-calmodulin-dependent protein kinase. This results in the inhibition of platelet aggregation and vasodilation.
**Why Each Wrong Option is Incorrect**
**Option A:** Dipyridamole does not act by inhibiting the enzyme adenylyl cyclase, which is responsible for producing cAMP. Inhibiting adenylyl cyclase would actually decrease cAMP levels and promote platelet activation.
**Option B:** Dipyridamole does not act by blocking the platelet-derived growth factor (PDGF) receptor. While PDGF is involved in platelet activation, dipyridamole's mechanism of action is not related to PDGF receptor blockade.
**Option C:** Dipyridamole does not act by inhibiting the enzyme thromboxane A2 synthase. While thromboxane A2 is involved in platelet aggregation, dipyridamole's mechanism of action is not related to thromboxane A2 synthase inhibition.
**Clinical Pearl / High-Yield Fact**
Dipyridamole is often used in conjunction with aspirin to prevent stroke and other cardiovascular events in patients with atrial fibrillation or other conditions. This combination therapy takes advantage of the complementary mechanisms of action of these two antiplatelet medications.
**Correct Answer:** C. Inhibiting the enzyme phosphodiesterase.